- Investing Ideas
- U.S. Pharmaceuticals & Biotech Breakout Stocks
U.S. Pharmaceuticals & Biotech Breakout Stocks
Results
16
Stocks where the price continues to rise after more than a year of consistent gains.
16 companies
AbCellera Biologics
Market Cap: US$3.7b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$11.38
7D
21.8%
1Y
143.7%
Eton Pharmaceuticals
Market Cap: US$1.7b
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$58.86
7D
34.8%
1Y
259.6%
Omeros
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
OMER
US$17.19
7D
26.2%
1Y
306.9%
Climb Bio
Market Cap: US$937.9m
A clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
CLYM
US$16.33
7D
20.6%
1Y
673.9%
Assembly Biosciences
Market Cap: US$670.9m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$32.95
7D
23.2%
1Y
27.9%
Camp4 Therapeutics
Market Cap: US$341.4m
A clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
CAMP
US$5.44
7D
28.9%
1Y
192.5%
Cue Biopharma
Market Cap: US$143.7m
A clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders.
CUE
US$34.20
7D
31.0%
1Y
39.2%
RenovoRx
Market Cap: US$63.1m
A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.40
7D
20.7%
1Y
48.9%
Apollomics
Market Cap: US$51.4m
A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
APLM
US$23.40
7D
31.1%
1Y
310.5%
Brainstorm Cell Therapeutics
Market Cap: US$10.9m
A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
BCLI
US$0.99
7D
25.3%
1Y
59.7%
Hepion Pharmaceuticals
Market Cap: US$6.7m
A biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States.
HEPA
US$0.075
7D
25.0%
1Y
15.7%
Vaxxinity
Market Cap: US$3.2m
A biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.
VAXX
US$0.025
7D
25,400.0%
1Y
25,400.0%
Enzolytics
Market Cap: US$2.9m
A drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
ENZC
US$0.0006
7D
20.0%
1Y
0%
GB Sciences
Market Cap: US$211.8k
A plant-based research and biopharmaceutical drug development company.
GBLX
US$0.0004
7D
33.3%
1Y
100.0%
Hero Technologies
Market Cap: US$56.4k
Operates as an early-stage cannabis company.
HENC
US$0.0001
7D
9,900.0%
1Y
0%
Pressure BioSciences
Market Cap: US$30.1k
Develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide.
PBIO
US$0.0007
7D
250.0%
1Y
600.0%